Exchange: NYSE·Updated 07:34 PM EST

GMED News

News
all
press releases
HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance?
Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
Zacks
HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance?
Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
Zacks
More News
Reasons to Add HealthEquity Stock to Your Portfolio for Now
HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.
Zacks
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline
Solventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
Zacks
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
Globus Medical cuts its 2026 revenue outlook amid spine launch delays and weak Nevro sales while shifting its focus to new products and growth opportunities in 2027.
Zacks
XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
DENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
Zacks
Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Globus Medical (GMED) Q3 Earnings Top Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +2.50% and -3.69%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat
BD stock lost 6.4% in pre-market trading despite Q4 earnings and revenue beat, as its subdued fiscal 2027 revenue growth outlook raises investor concerns.
Zacks
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Zacks
MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
McKesson's Q2 fiscal 2027 earnings beat estimates on specialty growth and higher prescription volumes, prompting raised guidance despite an after-hours stock dip.
Zacks

Advertisement|Remove ads.